Semaglutide
STEP HFpEF DM
Novo Nordisk · Phase 3 · Completed · Enrollment 617
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide 2.4 mg once weekly (OW) | n/r | n/r | n/r | n/r |
| Semaglutide placebo OW | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide 2.4 mg once weekly (OW): endpoint not reported
- Semaglutide placebo OW: endpoint not reported